StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
419
This month
1
This week
1
This year
29
Publishing Date
2024 - 02 - 01
3
2023 - 04 - 14
3
2023 - 04 - 04
2
2023 - 03 - 30
2
2023 - 02 - 13
2
2023 - 02 - 07
2
2023 - 01 - 23
2
2023 - 01 - 19
2
2022 - 12 - 13
2
2022 - 12 - 08
3
2022 - 11 - 11
2
2022 - 11 - 01
2
2022 - 09 - 16
2
2022 - 09 - 14
2
2022 - 09 - 13
2
2022 - 08 - 15
2
2022 - 07 - 29
2
2022 - 07 - 11
3
2022 - 05 - 31
2
2022 - 05 - 26
3
2022 - 05 - 09
4
2022 - 05 - 03
2
2022 - 04 - 12
3
2022 - 03 - 25
3
2022 - 03 - 16
2
2022 - 02 - 28
2
2022 - 02 - 14
2
2021 - 12 - 16
2
2021 - 11 - 17
2
2021 - 11 - 16
2
2021 - 11 - 12
2
2021 - 11 - 09
2
2021 - 11 - 04
2
2021 - 10 - 28
2
2021 - 10 - 27
2
2021 - 10 - 21
2
2021 - 10 - 18
2
2021 - 10 - 12
2
2021 - 10 - 04
2
2021 - 09 - 30
2
2021 - 09 - 22
2
2021 - 09 - 15
3
2021 - 08 - 25
3
2021 - 08 - 06
2
2021 - 08 - 05
4
2021 - 08 - 03
2
2021 - 08 - 02
2
2021 - 07 - 30
3
2021 - 07 - 28
3
2021 - 07 - 20
3
2021 - 06 - 16
2
2021 - 05 - 21
2
2021 - 05 - 04
2
2021 - 05 - 03
3
2021 - 04 - 28
2
2021 - 04 - 19
2
2021 - 04 - 14
2
2021 - 03 - 15
3
2021 - 02 - 26
2
2020 - 12 - 10
2
Sector
Commercial services
5
Communications
4
Consumer durables
2
Consumer non-durables
3
Consumer services
2
Electronic technology
3
Finance
4
Health services
2
Health technology
419
Manufacturing
23
N/a
9
Process industries
5
Producer manufacturing
3
Professional, scientific, and technical services
5
Technology services
4
Utilities
2
Tags
Alliances
16
Antibody
7
Application
11
Approval
20
Asia
14
Biotech
6
Biotech-bay
10
Biotech-beach
17
Cabometyx
7
Cancer
34
Cell carcinoma
7
Children
7
Clinical-trials-phase-ii
10
Clinical-trials-phase-iii
23
Collaboration
15
Covid
11
Covid-19
10
Disease
32
Drug
29
Earnings
23
Events
8
Expected
7
Fda
16
Financial
17
Financial results
13
Gene therapies
6
Gene therapy
6
Genetown
22
Global
51
Growth
29
Hereditary angioedema
8
Injection
6
Japan
7
License
13
Liver
16
Market
84
Money
11
N/a
184
Nivolumab
6
Partnership
6
People
7
Pharmaceutical
17
Phase 2
6
Phase 3
19
Positive
14
Product-news
10
Rare
11
Reach
11
Renal
7
Report
45
Research
41
Results
58
Sars-cov-2
6
Study
8
Takhzyro
7
Therapeutics
37
Therapy
42
Treatment
49
Trial
36
Vaccine
27
Entities
Abbott laboratories
10
Abbvie inc.
31
Adma biologics inc
4
Adverum biotechnologies, inc.
2
Agios pharmaceuticals, inc.
2
Alnylam pharmaceuticals, inc.
2
Altria group
2
Amgen inc.
23
Amicus therapeutics, inc.
2
Arcturus therapeutics holdings inc.
26
Arrowhead pharmaceuticals, inc.
12
Astellas pharma inc
12
Astrazeneca plc
29
Avalonbay communities, inc.
2
Bausch health companies inc.
7
Baxter international inc.
5
Biocryst pharmaceuticals, inc.
2
Biogen inc.
6
Bristol-myers squibb company
43
Catalent, inc.
3
Centogene n.v.
5
Codexis, inc.
3
Csl ltd
4
Eli lilly and company
42
Exelixis, inc.
27
Genmab a/s
3
Gilead sciences, inc.
15
Glaxosmithkline plc
34
Global blood therapeutics, inc.
3
Grifols, s.a.
6
Hutchison china meditech limited
7
Immunogen, inc.
3
Incyte corporation
16
Jazz pharmaceuticals plc
6
Johnson & johnson
82
Karyopharm therapeutics inc.
7
Logicbio therapeutics, inc.
4
Macrogenics, inc.
4
Mallinckrodt plc
4
Moderna, inc.
5
Morphosys ag
13
Nektar therapeutics
3
Neurocrine biosciences, inc.
9
Novartis ag
58
Novavax, inc.
4
Novo nordisk a/s
15
Orange
4
Ovid therapeutics inc.
6
Pfizer, inc.
23
Regeneron pharmaceuticals, inc.
6
Sanofi
59
Takeda pharmaceutical company limited
419
Teva pharmaceutical industries limited
5
Teva pharmaceutical industries ltd
20
Thermo fisher scientific inc
7
Ucb s.a.
8
Vericel corporation
3
Vertex pharmaceuticals incorporated
4
Viatris inc.
7
Xencor, inc.
12
Symbols
AAPL
1192
ABB
1422
ABBV
1022
ABLZF
1161
ABT
1783
ACN
600
AMGN
741
ARVL
4282
AZN
664
BDX
796
BMY
662
BNPQF
1763
BNPQY
1763
CSCO
895
DHR
785
ERIC
1605
F
641
FNCTF
7164
FRBA
595
GE
915
GLAXF
657
GOOG
1270
GOOGL
1269
GSK
883
HON
1777
HUBS
1400
IBM
654
INTC
954
IT
590
JNJ
4564
LLY
1706
LTUM
970
LYV
717
MDT
1283
MMM
938
MS
4276
MSFT
1199
MT
588
NOC
588
NOK
897
NOKBF
971
NVO
630
NVS
1240
NVSEF
1030
ORCL
1156
PCRFF
650
PCRFY
650
PFE
692
PHG
962
PPRUF
1126
PPRUY
1127
SAP
1472
SAPGF
1226
SNOW
794
SNY
4529
SNYNF
3587
TEVJF
630
TMO
1619
VZ
1210
XYF
674
Exchanges
Amex
1
Nasdaq
268
Nyse
419
Crawled Date
2024 - 02 - 01
3
2023 - 04 - 14
3
2023 - 01 - 23
2
2023 - 01 - 19
2
2022 - 12 - 13
2
2022 - 12 - 08
3
2022 - 11 - 11
2
2022 - 11 - 01
2
2022 - 09 - 16
2
2022 - 09 - 14
2
2022 - 09 - 13
2
2022 - 08 - 15
2
2022 - 07 - 29
2
2022 - 07 - 11
3
2022 - 07 - 01
2
2022 - 05 - 31
2
2022 - 05 - 27
2
2022 - 05 - 26
2
2022 - 05 - 09
4
2022 - 05 - 03
2
2022 - 04 - 12
3
2022 - 03 - 25
3
2022 - 03 - 16
2
2022 - 02 - 28
2
2022 - 02 - 18
2
2022 - 02 - 14
2
2022 - 02 - 03
2
2022 - 01 - 07
2
2021 - 12 - 16
2
2021 - 11 - 17
2
2021 - 11 - 16
2
2021 - 11 - 12
2
2021 - 11 - 09
2
2021 - 11 - 04
2
2021 - 10 - 28
2
2021 - 10 - 27
2
2021 - 10 - 21
2
2021 - 10 - 12
2
2021 - 10 - 04
2
2021 - 09 - 30
2
2021 - 09 - 22
2
2021 - 09 - 15
3
2021 - 08 - 25
3
2021 - 08 - 06
2
2021 - 08 - 05
4
2021 - 08 - 03
2
2021 - 08 - 02
2
2021 - 07 - 30
3
2021 - 07 - 28
3
2021 - 07 - 20
3
2021 - 06 - 16
2
2021 - 05 - 21
2
2021 - 05 - 04
2
2021 - 05 - 03
3
2021 - 04 - 28
2
2021 - 04 - 19
2
2021 - 03 - 15
3
2021 - 03 - 04
6
2021 - 02 - 26
2
2020 - 12 - 10
2
Crawled Time
00:00
15
00:20
1
01:00
13
02:00
7
03:00
1
04:00
2
04:20
1
05:00
4
06:00
3
07:00
3
08:00
13
09:00
26
09:10
1
10:00
15
10:48
5
11:00
22
12:00
42
12:15
5
12:20
2
12:30
4
13:00
36
13:15
3
13:20
6
13:30
7
14:00
24
14:02
1
14:15
1
14:20
6
14:30
3
15:00
20
15:15
2
15:20
3
15:30
3
16:00
10
17:00
17
18:00
16
18:11
1
19:00
11
19:56
1
20:00
12
20:20
1
21:00
11
22:00
23
23:00
16
Source
investors.ovidrx.com
6
www.biospace.com
234
www.chi-med.com
1
www.fda.gov
2
www.globenewswire.com
22
www.prnewswire.com
154
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
symbols :
TAK
save search
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
Published:
2022-04-20
(Crawled : 12:00)
- biospace.com/
TAK
|
$13.23
0.38%
0.0%
2.3M
|
Health Technology
|
-8.57%
|
O:
1.17%
H:
0.68%
C:
0.27%
JNJ
|
$144.45
-2.13%
0.03%
13M
|
Health Technology
|
-19.9%
|
O:
1.06%
H:
1.14%
C:
0.91%
ARCT
4
|
$30.15
2.87%
2.79%
390K
|
Health Technology
|
19.56%
|
O:
-20.04%
H:
28.04%
C:
21.44%
covid-19
arct-154
vaccine
mrna
phase 3
European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistan...
Published:
2022-11-11
(Crawled : 11:00)
- biospace.com/
RLYB
|
$1.81
-1.09%
-1.1%
740K
|
|
-73.13%
|
O:
-25.22%
H:
14.77%
C:
11.58%
TAK
|
$13.23
0.38%
0.0%
2.3M
|
Health Technology
|
-4.41%
|
O:
-0.87%
H:
0.95%
C:
0.95%
cytomegalovirus
treatment
disease
infection
Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
Published:
2021-08-02
(Crawled : 14:00)
- biospace.com/
TAK
|
$13.23
0.38%
0.0%
2.3M
|
Health Technology
|
-21.39%
|
O:
-0.36%
H:
0.75%
C:
-0.18%
JNJ
|
$144.45
-2.13%
0.03%
13M
|
Health Technology
|
-16.23%
|
O:
0.02%
H:
0.21%
C:
-0.12%
ARCT
4
|
$30.15
2.87%
2.79%
390K
|
Health Technology
|
-2.78%
|
O:
6.36%
H:
9.92%
C:
5.16%
vaccine
trial
approval
sars-cov-2
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
Published:
2023-06-15
(Crawled : 14:20)
- globenewswire.com
TAK
|
$13.23
0.38%
0.0%
2.3M
|
Health Technology
|
-17.78%
|
O:
-0.31%
H:
0.78%
C:
0.69%
HCM
|
$16.66
-5.66%
-6.0%
110K
|
Health Technology
|
36.72%
|
O:
2.46%
H:
9.6%
C:
5.6%
authorization
cancer
application
Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance
Published:
2022-11-01
(Crawled : 12:00)
- biospace.com/
TAK
|
$13.23
0.38%
0.0%
2.3M
|
Health Technology
|
0.08%
|
O:
0.68%
H:
1.05%
C:
-0.23%
NBIX
|
$133.06
1.0%
0.99%
1M
|
Health Technology
|
15.52%
|
O:
-0.1%
H:
7.37%
C:
3.79%
sales
ingrezza
financial
results
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
Published:
2022-11-01
(Crawled : 12:00)
- biospace.com/
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
43.49%
|
O:
1.13%
H:
0.0%
C:
0.0%
TAK
|
$13.23
0.38%
0.0%
2.3M
|
Health Technology
|
0.08%
|
O:
0.68%
H:
1.05%
C:
-0.23%
NVS
|
$93.2
-1.28%
0.0%
1.6M
|
Health Technology
|
14.41%
|
O:
0.47%
H:
0.09%
C:
-0.55%
XNCR
|
$18.94
-5.82%
-6.18%
500K
|
Health Technology
|
-32.43%
|
O:
1.07%
H:
2.51%
C:
-0.11%
MOR
|
$17.91
-0.61%
-0.61%
560K
|
Health Technology
|
270.87%
|
O:
3.1%
H:
1.8%
C:
-0.6%
INCY
|
$53.23
-0.37%
-0.38%
1.5M
|
Health Technology
|
-28.41%
|
O:
1.59%
H:
7.26%
C:
1.89%
financial
results
Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
Published:
2021-07-28
(Crawled : 15:00)
- biospace.com/
TAK
|
$13.23
0.38%
0.0%
2.3M
|
Health Technology
|
-21.11%
|
O:
0.42%
H:
2.14%
C:
1.72%
JNJ
|
$144.45
-2.13%
0.03%
13M
|
Health Technology
|
-16.34%
|
O:
0.04%
H:
0.38%
C:
-0.32%
ARCT
4
|
$30.15
2.87%
2.79%
390K
|
Health Technology
|
-3.09%
|
O:
-0.19%
H:
6.93%
C:
6.54%
phase 2
approval
PM360 Announces Winners of The Seventh Annual ELITE Awards
Published:
2021-05-14
(Crawled : 13:15)
- prnewswire.com
TAK
|
$13.23
0.38%
0.0%
2.3M
|
Health Technology
|
-21.9%
|
O:
0.47%
H:
0.82%
C:
0.59%
TARS
|
$34.945
0.01%
0.01%
460K
|
Health Technology
|
17.83%
|
O:
0.54%
H:
0.74%
C:
-1.07%
MYGN
F
|
$18.91
-1.36%
-1.37%
480K
|
Health Technology
|
-26.24%
|
O:
0.23%
H:
6.57%
C:
6.5%
awards
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023
Published:
2023-02-06
(Crawled : 13:00)
- biospace.com/
TAK
|
$13.23
0.38%
0.0%
2.3M
|
Health Technology
|
-17.16%
|
O:
-0.94%
H:
0.51%
C:
-0.13%
VYGR
|
$7.98
-3.16%
-3.26%
400K
|
Health Technology
|
-1.48%
|
O:
-1.11%
H:
3.87%
C:
0.5%
NBIX
|
$133.06
1.0%
0.99%
1M
|
Health Technology
|
20.87%
|
O:
-5.23%
H:
6.35%
C:
0.71%
financial
Global Lupus Therapeutic Market to Surpass US$ 5,408.1 Million by 2030, Says Coherent Market Insights
Published:
2022-03-16
(Crawled : 18:00)
- prnewswire.com
GLAXF
|
$20.2
-14.18%
510
|
Health Technology
|
-3.16%
|
O:
-0.46%
H:
3.49%
C:
3.49%
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
15.32%
|
O:
2.25%
H:
0.0%
C:
0.0%
UCBJY
|
$63.0
-4.38%
11K
|
Manufacturing
|
14.75%
|
O:
1.41%
H:
2.33%
C:
0.04%
TAK
|
$13.23
0.38%
0.0%
2.3M
|
Health Technology
|
-8.7%
|
O:
2.07%
H:
1.62%
C:
1.56%
NVS
|
$93.2
-1.28%
0.0%
1.6M
|
Health Technology
|
10.19%
|
O:
0.74%
H:
0.0%
C:
0.0%
GSK
|
$39.95
-1.36%
0.0%
2.4M
|
Health Technology
|
-4.2%
|
O:
0.41%
H:
0.0%
C:
0.0%
BMY
|
$48.26
-0.52%
0.04%
12M
|
Health Technology
|
-30.81%
|
O:
0.26%
H:
0.31%
C:
-0.39%
SNY
|
$45.81
-0.93%
-0.94%
1.4M
|
Health Technology
|
-10.83%
|
O:
0.82%
H:
0.0%
C:
0.0%
AUPH
|
$5.01
-0.6%
-0.6%
850K
|
Health Technology
|
-52.34%
|
O:
0.95%
H:
6.23%
C:
5.19%
AMGN
|
$265.64
0.05%
0.05%
2M
|
Health Technology
|
15.13%
|
O:
0.41%
H:
0.0%
C:
-0.37%
lupus
market
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
Published:
2024-02-07
(Crawled : 12:00)
- prnewswire.com
TAK
|
$13.23
0.38%
0.0%
2.3M
|
Health Technology
|
-6.57%
|
O:
0.07%
H:
0.42%
C:
0.07%
NBIX
|
$133.06
1.0%
0.99%
1M
|
Health Technology
|
-6.97%
|
O:
-5.57%
H:
6.04%
C:
0.96%
financial
results
Kadcyla Leads the Global Antibody Drug Conjugates Market with Extensive Use in Breast Cancer Treatment
Published:
2023-11-01
(Crawled : 18:00)
- prnewswire.com
ALPMY
|
$9.2715
-1.11%
500K
|
Manufacturing
|
-23.18%
|
O:
-1.46%
H:
3.67%
C:
3.26%
ZYME
|
$8.95
-1.54%
-1.56%
260K
|
Health Technology
|
27.21%
|
O:
1.14%
H:
0.42%
C:
-0.7%
TAK
|
$13.23
0.38%
0.0%
2.3M
|
Health Technology
|
-3.08%
|
O:
1.03%
H:
0.73%
C:
0.58%
ADCT
|
$4.44
1.6%
0.0%
240K
|
Health Technology
|
561.6%
|
O:
-0.16%
H:
6.42%
C:
4.49%
ABBV
|
$162.54
0.54%
0.0%
4.8M
|
Health Technology
|
14.09%
|
O:
-0.86%
H:
0.0%
C:
0.0%
STRO
M
|
$3.94
-4.83%
-5.08%
770K
|
Health Technology
|
52.71%
|
O:
0.39%
H:
3.86%
C:
3.86%
IMGN
|
$31.23
0.03%
49M
|
Health Technology
|
109.1%
|
O:
5.09%
H:
5.48%
C:
-1.27%
GILD
|
$67.32
-0.64%
-0.64%
5M
|
Health Technology
|
-16.06%
|
O:
-0.47%
H:
1.88%
C:
1.78%
EXEL
4
|
$22.83
0.57%
0.57%
1.7M
|
Health Technology
|
7.33%
|
O:
-2.62%
H:
1.17%
C:
-1.66%
drug
antibody
breast
cancer
treatment
global
market
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
Published:
2023-11-02
(Crawled : 13:00)
- biospace.com/
TAK
|
$13.23
0.38%
0.0%
2.3M
|
Health Technology
|
-3.08%
|
O:
1.03%
H:
0.73%
C:
0.58%
LLY
|
$746.74
-0.54%
1.01%
2.5M
|
Health Technology
|
35.13%
|
O:
4.42%
H:
0.0%
C:
0.0%
IMGN
|
$31.23
0.03%
49M
|
Health Technology
|
109.1%
|
O:
5.09%
H:
5.48%
C:
-1.27%
financial
results
Global Rheumatology Therapeutics Market Research Report to 2027 - Featuring AbbVie, Amgen and Beckman Coulter Among Others
Published:
2022-04-26
(Crawled : 13:20)
- prnewswire.com
SNYNF
|
$92.966
-2.18%
630
|
Health Technology
|
-16.01%
|
O:
-1.81%
H:
0.0%
C:
0.0%
AZNCF
|
$135.94
-4.19%
770
|
Health Technology
|
4.62%
|
O:
3.09%
H:
0.0%
C:
-2.9%
UCBJY
|
$63.0
-4.38%
11K
|
Manufacturing
|
8.35%
|
O:
-0.33%
H:
0.0%
C:
-1.56%
TMO
|
$554.55
-0.6%
0.0%
1M
|
Health Technology
|
2.18%
|
O:
-1.19%
H:
0.0%
C:
0.0%
TAK
|
$13.23
0.38%
0.0%
2.3M
|
Health Technology
|
-9.2%
|
O:
-0.48%
H:
0.0%
C:
0.0%
PFE
A
|
$25.69
-0.85%
0.1%
29M
|
Health Technology
|
-46.27%
|
O:
3.08%
H:
0.0%
C:
0.0%
JNJ
|
$144.45
-2.13%
0.03%
13M
|
Health Technology
|
-20.89%
|
O:
2.0%
H:
0.0%
C:
0.0%
LLY
|
$746.74
-0.54%
1.01%
2.5M
|
Health Technology
|
161.83%
|
O:
0.34%
H:
1.41%
C:
-1.17%
BMY
|
$48.26
-0.52%
0.04%
12M
|
Health Technology
|
-36.54%
|
O:
-0.09%
H:
1.26%
C:
-0.51%
VRTX
|
$394.17
-0.8%
-0.82%
690K
|
Health Technology
|
45.09%
|
O:
-0.22%
H:
0.43%
C:
-1.25%
SNY
|
$45.81
-0.93%
-0.94%
1.4M
|
Health Technology
|
-15.12%
|
O:
-0.11%
H:
0.0%
C:
0.0%
RIGL
|
$1.13
-1.74%
-1.77%
750K
|
Health Technology
|
-56.98%
|
O:
-0.38%
H:
4.92%
C:
-4.55%
REGN
|
$894.265
-0.48%
-0.48%
610K
|
Health Technology
|
29.52%
|
O:
-0.72%
H:
0.0%
C:
0.0%
GILD
|
$67.32
-0.64%
-0.64%
5M
|
Health Technology
|
7.44%
|
O:
-0.13%
H:
0.0%
C:
0.0%
AZN
|
$68.27
-0.67%
-0.67%
3.8M
|
Health Technology
|
3.49%
|
O:
-0.03%
H:
0.53%
C:
-1.33%
research
report
therapeutics
market
ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan
Published:
2023-08-28
(Crawled : 12:00)
- biospace.com/
TAK
|
$13.23
0.38%
0.0%
2.3M
|
Health Technology
|
-12.9%
|
O:
0.07%
H:
0.59%
C:
0.53%
IMGN
|
$31.23
0.03%
49M
|
Health Technology
|
93.68%
|
O:
-7.01%
H:
4.87%
C:
3.6%
elahere
japan
collaboration
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
Published:
2023-08-01
(Crawled : 15:00)
- biospace.com/
TAK
|
$13.23
0.38%
0.0%
2.3M
|
Health Technology
|
-13.3%
|
O:
-2.23%
H:
2.28%
C:
1.34%
XNCR
|
$18.94
-5.82%
-6.18%
500K
|
Health Technology
|
-22.11%
|
O:
-0.74%
H:
0.0%
C:
0.0%
REPL
|
$7.15
0.42%
0.42%
680K
|
Health Technology
|
-65.22%
|
O:
2.63%
H:
1.14%
C:
-2.65%
MOR
|
$17.91
-0.61%
-0.61%
560K
|
Health Technology
|
144.22%
|
O:
-0.14%
H:
4.77%
C:
4.77%
MGNX
4
|
$16.67
-1.59%
-1.62%
630K
|
Health Technology
|
249.69%
|
O:
0.0%
H:
4.19%
C:
2.31%
INCY
|
$53.23
-0.37%
-0.38%
1.5M
|
Health Technology
|
-16.48%
|
O:
2.75%
H:
0.44%
C:
-2.72%
financial
results
Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results
Published:
2021-08-05
(Crawled : 22:00)
- biospace.com/
TAK
|
$13.23
0.38%
0.0%
2.3M
|
Health Technology
|
-19.82%
|
O:
0.0%
H:
0.61%
C:
0.55%
JNJ
|
$144.45
-2.13%
0.03%
13M
|
Health Technology
|
-16.68%
|
O:
0.28%
H:
0.0%
C:
-0.09%
ARWR
|
$23.67
-1.42%
-1.44%
800K
|
Health Technology
|
-64.2%
|
O:
-0.27%
H:
4.66%
C:
3.2%
results
Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder
Published:
2021-06-10
(Crawled : 12:00)
- biospace.com/
TAK
|
$13.23
0.38%
0.0%
2.3M
|
Health Technology
|
-22.5%
|
O:
0.35%
H:
1.75%
C:
1.34%
CDXS
|
$2.74
1.86%
1.82%
320K
|
Process Industries
|
-87.12%
|
O:
-0.05%
H:
4.39%
C:
3.16%
genetic
gene therapy
therapy
collaboration
license
gene therapies
rare
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
Published:
2021-04-14
(Crawled : 00:00)
- biospace.com/
TAK
|
$13.23
0.38%
0.0%
2.3M
|
Health Technology
|
-22.18%
|
O:
0.0%
H:
1.09%
C:
0.35%
BMY
|
$48.26
-0.52%
0.04%
12M
|
Health Technology
|
-24.1%
|
O:
0.27%
H:
0.33%
C:
0.09%
EXEL
4
|
$22.83
0.57%
0.57%
1.7M
|
Health Technology
|
-3.67%
|
O:
-0.38%
H:
4.2%
C:
3.09%
treatment
europe
renal
approval
cell carcinoma
nivolumab
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
Published:
2022-01-25
(Crawled : 13:30)
- biospace.com/
TAK
|
$13.23
0.38%
0.0%
2.3M
|
Health Technology
|
-8.63%
|
O:
-0.76%
H:
2.02%
C:
1.04%
JNJ
|
$144.45
-2.13%
0.03%
13M
|
Health Technology
|
-11.36%
|
O:
-0.37%
H:
3.73%
C:
3.25%
ARCT
4
|
$30.15
2.87%
2.79%
390K
|
Health Technology
|
21.0%
|
O:
0.24%
H:
4.13%
C:
1.44%
arct-154
trial
therapeutics
response
sars-cov-2
report
pons
antibody
← Previous
1
2
3
4
5
6
7
8
9
…
20
21
Next →
Gainers vs Losers
58%
42%
Top 10 Gainers
WISA
4
|
$6.06
246.29%
71.12%
200M
|
Electronic Technology
VIAO
|
$0.265
-13.96%
35.85%
960K
|
Electronic Technology
JAGX
|
$0.178
49.83%
33.26%
600M
|
Health Technology
SXTC
|
$1.68
43.59%
30.36%
34M
|
Health Technology
DYNT
|
$0.531
43.36%
30.24%
22M
|
Health Technology
KA
|
$0.4796
41.06%
29.11%
5.3M
|
Manufacturing
PALI
|
$5.86
40.87%
29.01%
29M
|
Manufacturing
CLNN
|
$0.319
-3.74%
28.75%
6.3M
|
BSGM
|
$1.52
38.18%
27.63%
3.3M
|
Health Technology
MCBC
|
$13.67
37.66%
27.36%
2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.